


Claims



What is claimed is :

1. An use of derivatives of succinate esters of general formula (I) in the manufacture of the medicine for preventing or treating dementia:



(I)


wherein,



R_5 is selected from non-branched or branched C_{1-6} alkyls;

The configuration of chiral center at C-2 and C-3 are 2R3S, 2R3R, 2S3S and 2S3R respectively.




2. The use according to claim 1, characterized in that said compound of formula (I) is:








(I)






Wherein R₅ is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl; and R₁, R₂, R₃, and R₄ are the same as that in claim 1.

3. The use according to claim 2 characterized in that said compounds include:





1,4-bis(β-D-glucopyranosyloxybenzyl)-2-β-D-glucopyranosyl-2-isobutylmalate (dactylorhin A) (W8);



4. The use according to claims 1 ~ 3, characterized in that said compounds include stereo-isomers and pharmaceutical acceptable salts.

5. The use according to claim 1, characterized in that said dementia includes Alzheimer' disease, vascular dementia, and learning and memory obstacle.
- 6 A pharmaceutical composition, comprising an effective amount of any one of the compounds according to claims 1 ~ 4 and a pharmaceutically acceptable carrier.
- 7 The pharmaceutical composition according to claim 6, characterized in that said pharmaceutical composition may be in the form of tablets, capsules, pills, injectable solutions, sustained released formulation, controled released formulation and various microparticle systems.
- 8 An use of extract of *Coeloglossum viride* (L.) Hartm. var. *bracteatum* (Willd.) Richter in the manufacture of the drugs for preventing or treating dementia.
- 9 The use according to claim 8, characterized in that said dementia includes Alzheimer' disease, vascular dementia and learning and memory obstacle.
- 10 A pharmaceutical composition, comprising an effective amount of extracts according to claim 8 and a pharmaceutically acceptable carrier.
- 11 The pharmaceutical composition according to claim 10, characterized in that said pharmaceutical composition may be in the form of tablets, capsules, pills, injectable solutions, sustained released formulation, controled released formulation and various microparticle systems.